Breaking News Instant updates and real-time market news.

BDX

Becton Dickinson

$259.29

1.68 (0.65%)

, DXCM

DexCom

$142.03

0.45 (0.32%)

04:55
08/30/18
08/30
04:55
08/30/18
04:55

William Blair to hold a field trip

11th Annual West Coast Med Tech Trip travels through San Diego, Los Angeles and San Francisco visiting various medical technology companies on August 27-30.

BDX

Becton Dickinson

$259.29

1.68 (0.65%)

DXCM

DexCom

$142.03

0.45 (0.32%)

GNMK

GenMark

$8.41

0.48 (6.05%)

HOLX

Hologic

$39.46

0.2 (0.51%)

ILMN

Illumina

$350.56

5.83 (1.69%)

NUVA

NuVasive

$70.16

1.195 (1.73%)

RMD

ResMed

$112.32

0.77 (0.69%)

SIEN

Sientra

$24.04

1.12 (4.89%)

EW

Edwards Lifesciences

$143.79

1.79 (1.26%)

GKOS

Glaukos

$62.87

18.08 (40.37%)

ALGN

Align Technology

$385.53

3.21 (0.84%)

INGN

Inogen

$257.14

4.94 (1.96%)

XENT

Intersect ENT

$29.05

0.15 (0.52%)

ISRG

Intuitive Surgical

$554.37

9.47 (1.74%)

IVTY

Invuity

$4.50

0.5 (12.50%)

NVRO

Nevro

$67.33

0.17 (0.25%)

PEN

Penumbra

$134.78

3.275 (2.49%)

VCYT

Veracyte

$12.25

-0.04 (-0.33%)

  • 05

    Sep

  • 05

    Sep

  • 11

    Sep

  • 12

    Sep

  • 06

    Nov

  • 15

    Nov

BDX Becton Dickinson
$259.29

1.68 (0.65%)

04/10/18
04/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Erinn Murphy citing Piper's 35th semi-annual teens survey in which Ulta Beauty overtook Sephora as the top brand for average-income teens. 2. Nvidia (NVDA) and Seagate (STX) were upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Live Nation (LYV) upgraded to Buy from Neutral at Citi with analyst Jason Bazinet saying the stock has sold off after the New York Times reported that the Department of Justice is investigating the company for antitrust violations. 4. Becton Dickinson (BDX) upgraded to Buy from Neutral at Citi with analyst Amit Hazan saying he sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. 5. Illinois Tool Works (ITW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Joe Ritchie saying the pullback in shares due to auto concerns provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/18
WBLR
06/19/18
NO CHANGE
WBLR
Outperform
Becton Dickinson management call 'very bullish,' says William Blair
William Blair analyst Brian Weinstein says his investor call yesterday with Becton Dickinson CEO Vince Forlenz was "very bullish." Management provided a look into the growth drivers in various businesses and noted the integration of C.R. Bard is progressing as well as, if not better than, the original deal model, Weinstein tells investors in a research note. The analyst got the sense that Becton's "business is in good shape at the present time." He keeps an Outperform rating on the shares.
06/21/18
JPMS
06/21/18
UPGRADE
Target $275
JPMS
Overweight
Becton Dickinson upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Robbie Marcus upgraded Becton Dickinson to Overweight and raised his price target for the shares to $275 from $250. The analyst sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. With sustainable 5% organic sales growth, a minimum of low-double-digit earnings growth "arguably a given for the foreseeable future," and sustainable 90% free cash flow conversion, Becton deserves a premium multiple even after factoring in its leverage, Marcus tells investors in a research note.
06/21/18
06/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying he believes the company's differentiated checkout experience should enable the company to continue taking share. 2. Verizon (VZ) and Charter (CHTR) were upgraded to Buy from Neutral at Goldman Sachs. 3. Terex (TEX) upgraded to Buy from Hold at Jefferies with analyst Stephen Volkmann saying Terex has underperformed both the S&P 500 Index and machinery peers year-to-date despite improving backlog and visibility into 2019. 4. AMC Entertainment (AMC) upgraded to Buy from Hold at Benchmark with analyst Mike Hickey saying he believes the company's new movie subscription service will succeed in driving incremental attendance and EBITDA. 5. Becton Dickinson (BDX) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying he sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DXCM DexCom
$142.03

0.45 (0.32%)

08/23/18
BARD
08/23/18
NO CHANGE
Target $160
BARD
Outperform
DexCom price target raised to $160 from $140 at Baird
Baird analyst Jeff Johnson raised his price target on DexCom to $160 from $140 following its acquisition of TypeZero Technologies. The analyst believes the deal is a strategic positive for the company as it expands the ecosystem management continues to build out. He also sees industry tailwinds remaining and still-conservative Street estimates. Johnson reiterated his Outperform rating on DexCom shares.
08/23/18
ADAM
08/23/18
NO CHANGE
Target $150
ADAM
Buy
DexCom price target raised to $150 from $125 at Canaccord
Canaccord analyst Kyle Rose raised his price target on DexCom to $150 from $125 following its announced acquisition of TypeZero Technologies, a private diabetes software company and a leading player in the development of artificial pancreas and diabetes decision support algorithms. The analyst believes the acquisition will help DexCom become a broader player in the diabetes ecosystem. Rose reiterated his Buy rating on DexCom shares.
08/22/18
PIPR
08/22/18
NO CHANGE
Target $150
PIPR
Overweight
DexCom TypeZero acquisition a 'smart strategic move', says Piper Jaffray
Piper Jaffray analyst JP Kim kept his Overweight rating and $150 price target on DexCom, saying the company's acquisition of TypeZero Technologies is a "smart strategic decision". Kim notes the purchase is moving the company one step closer to "becoming a diabetes service company that provides the best in class Continuous Glucose Monitoring and also decision support to patients". The analyst adds that his latest meeting with the management suggest that both demand and penetration of CGM has "accelerated meaningfully" over the last several months and is also sustainable.
08/20/18
LSCM
08/20/18
NO CHANGE
Target $60
LSCM
Buy
Tandem Diabetes price target raised to $60 from $35 at Lake Street
Lake Street analyst Brooks O'Neil affirmed a Buy rating on Tandem Diabetes Care (TNDM) and raised his price target to $60 from $35 following the U.S. commercial launch of its t:slim X2 insulin pump with Basal-IQ, which is integrated with Dexcom's (DXCM) G6 CGM. In a research note to investors, O'Neil contends that while the stock is up 36.4% in the 14 trading days since its Q2 earnings release, he believes it is "just getting going."
GNMK GenMark
$8.41

0.48 (6.05%)

11/03/17
ADAM
11/03/17
NO CHANGE
Target $10
ADAM
Buy
GenMark price target lowered to $10 from $14 at Canaccord
Canaccord analyst Mark Massaro lowered his price target on GenMark to $10 from $14 following mixed Q3 results. The analyst also has forecasts well below consensus for Q4, citing lower utilization of ePlex placements in Europe and more of a shift to reagent rentals vs. capital placements. Massaro maintained his Buy rating on GenMark shares as he said his long-term thesis remains intact.
01/08/18
ADAM
01/08/18
NO CHANGE
ADAM
Buy
Week 52 flu data positive for Quidel, GenMark, says Canaccord
Canaccord analyst Mark Massaro said the CDC published its week 52 Influenza Surveillance Report and noted its increase and widespread flu incidence. He is encouraged by the data and now believes there is upside to revenue estimates for both Quidel (QDEL) and GenMark (GNMK). Massaro has a Buy ratings on both stocks, with a $52 price target on Quidel and a $10 price target on GenMark shares.
11/03/17
RAJA
11/03/17
DOWNGRADE
RAJA
Market Perform
GenMark downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Nicholas Jansen downgraded GenMark to Market Perform following the negative Q3 report and "sizable" reduction in Q4 guidance. The analyst said the combination of slower-than-anticipated European traction, a shift to more rentals, and delay in the US menu expansion are too much for his "patience to overcome."
07/31/18
ADAM
07/31/18
NO CHANGE
Target $10
ADAM
Buy
GenMark Q2 indicates company on track with growth initiatives, says Canaccord
Canaccord analyst Mark Massaro said GenMark delivered solid Q2 results, indicating the company remains on track with its growth initiatives. He said the outlook should help build investor confidence throughout the balance of the year and he continues to believe that a multi-billion dollar opportunity awaits. Massaro reiterated his Buy rating and raised his price target to $10 from $9 on GenMark shares.
HOLX Hologic
$39.46

0.2 (0.51%)

07/30/18
CHLM
07/30/18
NO CHANGE
CHLM
Hold
FDA warning to off-label competitors positive for Viveve, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt noted that the FDA published seven "Letters to Industry" that were sent to companies that may be violating the law for inappropriately marketing their energy-based devices for vaginal "rejuvenation," but noted that Viveve (VIVE) was not amongst them. He views this as a positive for Viveve, as it signals that the FDA is cracking down on the off-label promotion that he thinks has been a key commercial challenge for the company. Viveve is the only one in the space currently performing a trial for sexual function, placing it "miles ahead of the competition" in terms of obtaining an actual label, added Hewitt, who keeps a Hold rating on the stock due to concerns over the company's operating cash flow burn and uncertainty about financials. The Fly notes that Cynosure, a unit of Hologic (HOLX), was among the companies to receive an FDA warning.
05/25/18
EVER
05/25/18
NO CHANGE
Target $40.5
EVER
Outperform
Hologic relationship with Quest seems 'healthy,' says Evercore ISI
Evercore IS analyst Vijay Kumar sees "minimal risks" to Hologic (HOLX) from Quest Diagnostics' (DGX) and LabCorp's (LH) contract renegotiations with UnitedHealth (UNH) and Aetna (AET). He estimates Quest and LabCorp together account for about $200M of revenue for Hologic. Hologic received a Supplier Excellence award last year from Quest, which points to "healthy" relationship, Kumar tells investors in a research note. He believes the labs' new contracts bake in a mid-single digit pricing cut, leading a "manageable" 3c-4c of earnings impact to Hologic. Kumar has an Outperform rating on the shares with a $40.50 price target.
07/03/18
LEHM
07/03/18
NO CHANGE
Target $50
LEHM
Overweight
FDA update positive for near-term Hologic results, says Barclays
The FDA yesterday afternoon published its June update on industry mammography trends, which included "solid" 3D placements of 121, Barclays analyst Jack Meehan tells investors in a research note. The analyst believes the data are encouraging for near-term results for Hologic in the Breast Health segment. It also helps to show the sustainability of the "tomo tail" with Hologic approaching 60% conversion of its installed base, Meehan contends. He keeps an Overweight rating on Hologic with a $50 price target.
07/10/18
PIPR
07/10/18
NO CHANGE
Target $48
PIPR
Overweight
Hologic checks suggest Cynosure has recovered, says Piper Jaffray
Piper Jaffray analyst William Quirk says his Q3 channel checks suggest Hologic's Cynosure unit "may have finally turned the corner." Given the negative sentiment surrounding Hologic shares, now is a good time to add to positions, Quirk tells investors in a research note. The analyst now has eight months of weekly data on Cynosure and competitive lasers for sale at secondhand websites. Overall, aggregated used lasers on third party web resellers was down to 162 lasers from 179 in the March and December quarters, he points out. Quirk keeps an Overweight rating on Hologic with a $48 price target.
ILMN Illumina
$350.56

5.83 (1.69%)

08/07/18
08/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. SeaWorld (SEAS) upgraded to Neutral from Underperform at Macquarie with analyst Matthew Brooks saying management is executing well, 1H 2018 attendance growth was impressive, and a new 2020 EBITDA goal heading into a seasonally strong period changes is cautious thesis. 2. Alnylam (ALNY) upgraded to Buy from Hold at Stifel with analyst Paul Matteis citing a series of upcoming, likely positive pipeline events for givosiran, lumasiran and ALN-TTRsc02 along with his confidence in Alnylam's ability to have a dominant position in the TTR amyloidosis market over the longer-term. 3. NeoPhotonics (NPTN) upgraded to Buy from Neutral at B. Riley FBR with analyst Dave Kang saying he sees improving fundamentals and increased his estimates following the company's Q2 results. 4. Illumina (ILMN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Steve Beuchaw saying his prior thesis overestimated the impact of new products such as NovaSeq on utilization of the legacy installed base and failed to value critical new markets. 5. MasTec (MTZ) upgraded to Outperform from Neutral at Baird with analyst Andrew Wittmann saying concerns of weak cash flow and the MVP project work stoppage have already been priced into the stock and now offer a potential catalyst for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/18
ARGS
08/10/18
NO CHANGE
Target $372
ARGS
Buy
Illumina price target raised to $372 from $310 at Argus
Argus analyst Jasper Hellweg raised his price target on Illumina to $372 and kept his Buy rating while also raising his FY18 EPS view to $5.47 from $4.87. The analyst expects the company to "benefit from a recent CMS decision to provide Medicare coverage for cancer testing using the company's next-generation sequencers". Hellweg also cites Illumina's continued platform investments as they lower the "barriers to entry for smaller labs while increasing the functionality of its gene-sequencing systems".
08/07/18
MSCO
08/07/18
UPGRADE
MSCO
Equal Weight
Illumina upgraded to Equal Weight from Underweight at Morgan Stanley
08/07/18
08/07/18
UPGRADE
Target $320

Equal Weight
Illumina upgraded to Equal Weight on broadening support at Morgan Stanley
As previously reported, Morgan Stanley analyst Steve Beuchaw upgraded Illumina to Equal Weight from Underweight, admitting that his prior thesis overestimated the impact of new products such as NovaSeq on utilization of the legacy installed base and failed to value critical new markets. He now sees it as clear that broadening support for sequencing applications across faster-growing existing markets and into emerging markets de-risks the long-term outlook, Beuchaw tells investors. He raised his price target on Illumina shares to $320 from $210, stating that he sees a path to $40B in sales by 2040.
NUVA NuVasive
$70.16

1.195 (1.73%)

08/01/18
BTIG
08/01/18
INITIATION
Target $68
BTIG
Buy
NuVasive initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman initiated NuVasive with a Buy rating and a price target of $68 after its "mixed" Q2 results. The analyst states that while the company's revenues topped consensus based on the new product adoption and higher conversion in the U.S. Spinal Hardware market, gross margins were "challenged" by manufacturing scale. Zimmerman adds that NuVasive has kept its FY18 guidance, which is "beatable considering recent implant performance", but also warns that delaying margin improvement expectations could disappoint some investors. The analyst still believes that the company's valuation is attractive given the "improving top-line dynamics".
08/16/18
BTIG
08/16/18
NO CHANGE
Target $72
BTIG
Buy
NuVasive price target raised to $72 from $68 at BTIG
BTIG analyst Ryan Zimmerman raised his price target on NuVasive (NUVA) to $72 and kept his Buy rating following investor meetings with the management, saying the tone of the discussions was "decidedly more upbeat" after Q2 results and the company's FY18 guidance cut. The analyst states that he also "underappreciated" the potential for NuVasive's recent agreement with Siemens (SIEGY), as it expands the company's opportunity and provides better commercial support. Zimmerman expects investor interest in NuVasive shares to build heading into the full launch of the company's new Pulse system.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $75
PIPR
Overweight
NuVasive price target raised to $75 from $65 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for NuVasive to $75 following a deep dive into the company's new Pulse system, which management is set to unveil during the upcoming North American Spine Society meeting. Pulse represents a "compelling one-stop shop technology that will provide significantly more features than other navigation or robotic systems out there," O'Brien tells investors in a research note. The analyst believes Pulse addresses a $225M Greenfield market, where surgeons do not currently use any navigation, as well as a $125M per year replacement cycle category, where centers already use some type of surgical assistance. Further, he thinks NuVasive's partnership with Siemens will provide additional selling opportunities for both Pulse and LessRay. O'Brien keeps an Overweight rating on the shares.
06/27/18
06/27/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Molina Healthcare (MOH) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying he sees a high probability that Molina will retain its $2.2B 2020 Texas Medicaid contracts, but he does not like the downside risk heading into that Q3 re-procurement announcement. 2. Bio-Techne (TECH) downgraded to Hold from Buy at Deutsche Bank with analyst Dan Leonard stating that he increasingly questions the durability of its organic sales growth. 3. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Citi with analyst Liav Abraham saying he sees limited upside to valuation at current levels following the recent upward inflection in the share price. 4. NuVasive (NUVA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Bob Hopkins stating that he is skeptical NuVasive can consistently drive high single digit revenue growth due to robotics momentum in the marketplace and lack of a differentiated product. 5. Wesco (WCC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying its recent inability to translate increasing sales to incremental margin is reflective of the more competitive electrical distribution market it serves. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RMD ResMed
$112.32

0.77 (0.69%)

04/23/18
UBSW
04/23/18
DOWNGRADE
UBSW
Neutral
ResMed downgraded to Neutral from Buy at UBS
07/01/18
GSCO
07/01/18
INITIATION
GSCO
Buy
ResMed initiated with a Buy at Goldman Sachs
05/30/18
PIPR
05/30/18
NO CHANGE
Target $190
PIPR
Overweight
Inogen recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst JP McKim views the recent pullback in shares of Inogen (INGN) as unwarranted and recommends buying the shares at current levels. The analyst says his firm's survey of 66 home medical equipment providers indicates the shift to portable oxygen concentrators "remains strong." The market remains in the early innings of this conversion and Inogen is the best way to play this thematic trend, McKim tells investors in a research note. The analyst expects ResMed's (RMD) Mobi to launch this year, but does not expect it to be overly impactful to Inogen. Consensus numbers already reflect a deceleration in growth in the second half of 2018 which is unlikely to materialize, McKim contends. He keeps an Overweight rating on Inogen with a $190 price target.
05/31/18
05/31/18
NO CHANGE

Arcturus Therapeutics reinstates founder Joseph Payne as CEO
Arcturus Therapeutics (ARCT) has named Dr. Peter Farrell as Chairman of the Board of Directors of the company. Joseph E. Payne has been reinstated as President and CEO and Dr. Pad Chivukula has been reinstated as Chief Scientific Officer and COO. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (RMD).
SIEN Sientra
$24.04

1.12 (4.89%)

08/08/18
ADAM
08/08/18
NO CHANGE
Target $25
ADAM
Buy
Sientra price target raised to $25 from $19 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Sientra to $25 from $19 following strong Q2 results. The analyst said the results demonstrated management's commercial efforts in both breast products and miraDry. He believes the company can accelerate implant sales and regain market share through the second half of the year and sees them well positioned to enter the breast augmentation market as a meaningful market share taker in 2018. Rose reiterated his Buy rating on Sientra shares.
06/08/18
MAXM
06/08/18
DOWNGRADE
MAXM
Hold
Sientra downgraded to Hold from Buy at Maxim
06/08/18
MAXM
06/08/18
DOWNGRADE
MAXM
Hold
Sientra downgraded to Hold from Buy at Maxim
As previously reported, Maxim analyst Anthony Vendetti downgraded Sientra to Hold from Buy, telling investors that while he is optimistic on Sientra's long-term prospects, the valuation is significantly ahead of peer averages and the stock price has exceeded his 12-month target.
06/08/18
06/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Petrobras (PBR) downgraded to Neutral from Buy at UBS with analyst Luiz Carvalho citing reduced visibility on its long-term pricing policy after the company recently reduced prices, which significantly lowered the chances of the company selling its refining assets, keeping it a monopoly, and exposed it to possible interference depending on the government's policy approach and macro conditions. 2. Domino's Pizza (DPZ) downgraded to Hold from Buy at Maxim with analyst Stephen Anderson saying the company's comp performance and market share gains in the U.S., accelerated unit development worldwide, and mostly favorable cost outlook warrant a premium multiple, but believes these positives have been priced into shares. 3. Noble Energy (NBL) downgraded to Hold from Buy at Tudor Pickering. 4. Sientra (SIEN) downgraded to Hold from Buy at Maxim with analyst Anthony Vendetti saying that while he is optimistic on Sientra's long-term prospects, the valuation is significantly ahead of peer averages and the stock price has exceeded his 12-month target. 5. Quanex (NX) downgraded to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
EW Edwards Lifesciences
$143.79

1.79 (1.26%)

06/27/18
BERN
06/27/18
INITIATION
Target $165
BERN
Market Perform
Edwards Lifesciences initiated with a Market Perform at Bernstein
Bernstein analyst Lee Hambright started Edwards Lifesciences with a Market Perform and $165 price target. The analyst likes the long-term outlook for the transcatheter valve market, as aortic stenosis remains heavily undertreated, and the mitral/tricuspid adjacency opportunity is large. Further, he believes Edwards is well positioned to maintain share leadership. However, Hambright believes much of the upside is priced into the stock, and sees less well-appreciated stories elsewhere with similar EPS growth.
08/10/18
RHCO
08/10/18
NO CHANGE
Target $170
RHCO
Buy
Edwards Lifesciences price target lowered to $170 from $180 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Edwards Lifesciences to $170 citing increased Transcatheter aortic valve replacement, or TAVR, competition. The analyst keeps his Buy rating on the shareshowever, expecting the company to show increased TAVR momentum in the U.S. in Q4 thanks to the "Partner 3 CAP program and the Centera U.S. IDE which will likely cannibalize CoreValve".
07/10/18
BMOC
07/10/18
NO CHANGE
Target $162
BMOC
Outperform
Edwards Lifesciences price target raised to $162 from $150 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Edwards Lifesciences to $162 as part of her broader Medical Technology: Mid-year View research note. The analyst states that the company "continues to hold one of the better growth profiles in her coverage universe", penetrating the transcatheter aortic valve replacement market while tapping into the multi-billion dollar minimally invasive mitral and tricuspid valve markets . Wuensch keeps her Outperform rating on Edwards Lifesciences.
05/31/18
05/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wyndham Hotels & Resorts (WH) initiated with a Buy at Jefferies and an Overweight at JPMorgan. 2. Nxt-ID (NXTD) initiated with a Buy at Euro Pacific. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at Seaport Global. 4. Edwards Lifesciences (EW) and Medtronic (MDT) were initiated with an Outperform at Raymond James. 5. Rollins (ROL) initiated with a Hold at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GKOS Glaukos
$62.87

18.08 (40.37%)

08/29/18
JPMS
08/29/18
UPGRADE
JPMS
Overweight
Glaukos upgraded to Overweight from Neutral at JPMorgan
08/29/18
SPHN
08/29/18
NO CHANGE
Target $57
SPHN
Overweight
Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.
08/29/18
PIPR
08/29/18
NO CHANGE
Target $55
PIPR
Overweight
Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55
Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.
08/29/18
JPMS
08/29/18
UPGRADE
Target $75
JPMS
Overweight
JPMorgan upgrades Glaukos after 'main competitor' pulls product
As previously reported, JPMorgan analyst Robert Marcus upgraded Glaukos (GKOS) to Overweight from Neutral, calling Alcon's (NVS) voluntary withdrawal of its micro-stent from the market a "significant win" that opens up an opportunity for Glaukos to take back principally all of the sales being generated by CyPass. Stating that he's always been a firm believer in Glaukos' pipeline and technology, Marcus said competition had been the main factor keeping him on the sidelines. Now that its "main competitor" is out of the way, he sees Glaukos having a meaningful opportunity to recapture share and lead the market. Marcus raised his price target on the stock to $75 from $42.
ALGN Align Technology
$385.53

3.21 (0.84%)

07/26/18
LEER
07/26/18
NO CHANGE
Target $420
LEER
Outperform
Align Technology price target raised to $420 from $400 at Leerink
Leerink analyst Richard Newitter raised his price target for Align Technology to $420 from $400, citing a "solid" Q2 beat and increasing growth momentum. The analyst reiterates an Outperform rating on the shares.
07/26/18
BARD
07/26/18
NO CHANGE
Target $425
BARD
Outperform
Align Technology price target raised to $425 from $351 at Baird
Baird analyst Jeff Johnson raised his price target on Align Technology to $425 from $351 following strong Q2 results. The analyst noted case shipments, revenue, and earnings all exceeded estimates and also noted guidance was raised. He expects competitive pressures to remain muted and has increasing confidence in new products and evolving customer channels. Johnson reiterated his Outperform rating on Align Technology shares.
07/26/18
PIPR
07/26/18
NO CHANGE
Target $440
PIPR
Overweight
Align Technology price target raised to $440 from $425 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Align Technology to $440 after the company's Q2 results "easily topped" his estimates on the top and bottom lines. The outperformance was broad-based but iTero sales drove most of the upside, O'Brien tells investors in a research note. Clinicians do not buy scanners unless they intend to use a lot of aligners in the future, which is a 'very positive sign for the company's outlook," the analyst adds. O'Brien adds that while the Q3 guidance might be disappointing, he believes "this is part of the typical conservative playbook management employs." The analyst encourages investors to start or build positions in the name. He keeps an Overweight rating on Align Technology.
07/20/18
PIPR
07/20/18
NO CHANGE
Target $425
PIPR
Overweight
Align Technology price target raised to $425 from $325 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Align Technology to $425 after refreshing his analysis on new competition. The analyst continues to believe that competition will not dampen Align's growth profile. He says competing products are not as comprehensive and carry less of a discount to Invisalign than he previously assumed. Further, O'Brien thinks the market opportunity for clear aligners can grow larger than many investors realize. The analyst is confident that Align can sustainably grow sales 20%-30% for multiple years. He encourages investors to build positions, "even at current levels," and reiterates an Overweight rating on the shares.
INGN Inogen
$257.14

4.94 (1.96%)

08/21/18
STFL
08/21/18
INITIATION
Target $258
STFL
Buy
Inogen resumed with a Buy at Stifel
Stifel analyst Mathew Blackman resumed coverage of Inogen with a Buy rating and $258 target price, contending that it has the "right" technology, with the "right" business model, at the "right" time to exploit secular change in the global oxygen market.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $245
PIPR
Overweight
Inogen price target raised to $245 from $235 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target on Inogen to $245 and kept his Overweight rating after its "stellar" Q2 earnings and raised FY18 guidance. The analyst notes that the beat was "broad-based", featuring outperformance in DTC, BTB, and International segments, while also pointing to higher than expected gross margins in spite of the price discounting and higher operating expenditure than expected. McKim believes that Inogen's growth is "firing on all cylinders", with the company looking to expand its hiring pace and also holding discussions about a next-generation product.
08/08/18
NEED
08/08/18
NO CHANGE
Target $254
NEED
Strong Buy
Inogen price target raised to $254 from $215 at Needham
Needham analyst Mike Matson raised his price target on Inogen to $254 and kept his Strong Buy rating after its "significant" Q2 earnings and revenue beat along with its raised outlook for FY18. The analyst cites the company's direct-to-consumer business sales force expansion, rising margins, increased marketing, and the market shift to portable oxygen concentrators sustaining Inogen's strong growth.
07/16/18
PIPR
07/16/18
NO CHANGE
Target $235
PIPR
Overweight
Respironics go direct move negative headline for Inogen, says Piper Jaffray
Respironics recently updated its website to allow patients to buy direct from the company or to find the nearest durable medical equipment supplier that carries SimplyGo, Piper Jaffray analyst JP McKim tells investors in a research note. This is the first move by a competitor to go more direct and a negative headline to Inogen shares, the analyst contends. He notes the pricing is the same as Inogen's at $2,495 but also offers a monthly payment, assuming the patient qualifies for a loan. McKim believes that Inogen still has the advantage with years of direct-to-consumer advertising and a clear brand advantage. Nonetheless, competition "is seemingly heating up," he writes. However, the analyst sees room for multiple players and keeps an Overweight rating on Inogen with a $235 price target.
XENT Intersect ENT
$29.05

0.15 (0.52%)

08/01/18
PIPR
08/01/18
NO CHANGE
Target $40
PIPR
Overweight
Intersect ENT price target lowered to $40 from $45 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target for Intersect ENT to $40 from $45 after the company missed Q2 revenues and reduced full year 2018 guidance. Essentially, the disappointment in the quarter and for the outlook this year is the company's key new SINUVA product, which is ramping slower than expected due to reimbursement processing issues, he notes. Although this is disappointing and there is no guarantee that more road bumps in the launch will not pop up, the analyst still believes utilization will be quite strong and growth in 2019 and beyond will be among the best in small cap med tech. O'Brien reiterates an Overweight rating on the shares.
05/07/18
PIPR
05/07/18
NO CHANGE
Target $45
PIPR
Overweight
Piper says CMS made error, buy shares of Intersect ENT
This morning on the Centers for Medicare & Medicaid Services website, the agency, in a preliminary assessment, assigned Intersect ENT's Sinuva a J-Code that is based on a CPT code for its Propel technology, which will be deleted at the beginning of next year, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This appears to be an error on the part of CMS, the analyst adds. He fully anticipates it will be corrected in the final rule, which is expected to come out in November. O'Brien recommends investors take advantage of this morning's pullback to start or build positions in Intersect ENT. He doubts any clinicians would become concerned about the incorrect regulatory coding and does not anticipate any type of impact to the launch of Sinuva as a result. The analyst has an Overweight rating on Intersect ENT with a $45 price target. The stock in morning trading is down 6% to $39.15.
05/11/18
PIPR
05/11/18
NO CHANGE
Target $45
PIPR
Overweight
Intersect ENT selloff this week a buying opportunity, says Piper Jaffray
After hosting investor meetings with Intersect ENT management, Piper Jaffray analyst Matt O'Brien says J-code risk is overstated. Management spent a considerable amount of time discussing the preliminary J-Code ruling for Sinuva that came out earlier this week and noted that this was a clear clerical error, O'Brien tells investors in a research note. The analyst thinks the Sinuva launch is progressing well and that Intersect ENT's base business also has "significant room for growth." He believes investors should take advantage of the pullback earlier this week to start positions in the shares. O'Brien has an Overweight rating on Intersect ENT with a $45 price target.
05/07/18
LEER
05/07/18
NO CHANGE
LEER
Intersect ENT shares defended at Leerink
ISRG Intuitive Surgical
$554.37

9.47 (1.74%)

07/20/18
STFL
07/20/18
NO CHANGE
Target $600
STFL
Buy
Intuitive Surgical price target raised to $600 from $515 at Stifel
Stifel analyst Rick Wise said Intuitive Surgical "emphatically checked every important box" with its Q2 report, noting that its procedures growth, systems shipments, and EPS all meaningfully topped expectations. Following the report, he raised his 2018-2020 sales and EPS projections and increased his price target on the stock to $600. Wise keeps a Buy rating on Intuitive shares.
07/20/18
MSCO
07/20/18
NO CHANGE
Target $575
MSCO
Overweight
Intuitive Surgical price target increased to $575 from $535 at Morgan Stanley
Morgan Stanley analyst David Lewis increased his price target on Intuitive Surgical to $575 from $535, stating that "inflection in the core is evident" given the better than expected procedure growth and system upside reported in Q2. With trends in procedures and systems strong, he is confident in growth sustainability and he is additionally confident that Intuitive will not only to maintain technological leadership but materially expand its addressable market with new introductions, Lewis tells investors. He maintains an Overweight rating on Intuitive shares.
07/20/18
CANT
07/20/18
NO CHANGE
Target $620
CANT
Overweight
Intuitive Surgical price target raised to $620 from $510 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Intuitive Surgical to $620 from $510 following last night's Q2 results. The stock in premarket trading is up 3%, or $17.71, to $539.00. Quarter after quarter, Intuitive continues to justify its premium valuation, again significantly beating on all metrics, including sales and earnings, Bijou tells investors in a post-earnings research note. He notes the company posted 18% procedure growth for Q2, one of the strongest quarterly procedure growth figures year-over-year in the last five years. The analyst believes surgical robotics "remains at an early stage" and that Intuitive Surgical will drive adoption with its existing platforms and pipeline products. Bijou reiterates an Overweight rating on the shares.
07/20/18
RBCM
07/20/18
NO CHANGE
Target $550
RBCM
Sector Perform
Intuitive Surgical price target raised to $550 from $460 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Intuitive Surgical to $550 after its Q2 results, saying its momentum in general surgery continues, which allows the company to spend more to accelerate the development of its pipeline technologies. The analyst further notes that the raised procedure guidance of 14.5%-16.5% growth from 12%-15% appears reasonable, and there's potential for upside from the strong execution. Henry keeps his Sector Perform rating on Intuitive Surgical but also believes that the company is in the "early steep" part of the robotic U.S. general surgery adoption curve.
IVTY Invuity
$4.50

0.5 (12.50%)

02/28/18
PIPR
02/28/18
NO CHANGE
Target $12
PIPR
Overweight
Invuity interim CEO brings 'deep knowledge base,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Invuity is "at a turning point with compelling new products" such as PhotonBlade, and needs a "different kind of skill set to get it to that next level." Interim CEO Scott Flora brings a "deep knowledge base" into the interim CEO position and will guide the company to its next stage of growth before a permanent CEO candidate is found, O'Brien tells investors in a research after Philip Sawyer stepped down as CEO. The analyst keeps an Overweight rating on Invuity shares with a $12 price target.
09/25/17
PIPR
09/25/17
NO CHANGE
PIPR
Invuity's PhotonBlade announcement a 'welcome sight,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien maintained an Overweight rating and $10 price target on Invuity, and said shares were worth accumulating after the company's announcement after the close that it is resuming the full commercial launch of its PhotonBlade product and sees shipments beginning in the next few weeks.
NVRO Nevro
$67.33

0.17 (0.25%)

07/25/18
WBLR
07/25/18
NO CHANGE
WBLR
Outperform
Nevro patent ruling not as bad as it seems, says William Blair
William Blair analyst Margaret Kaczor says the summary judgement issued yesterday is not as bad as it seems for Nevro (NVRO). While the initial headline appears negative, the ruling is similar to the preliminary judgment published earlier this month, Kaczor tells investors in a research note. Though some of the claims in the patents have been invalidated, the remaining claims, which include frequency ranges of 1.5 kHz to 100 kHz, were not invalidated, the analyst adds. She points out, though, that the judge found Boston Scientific (BSX) did not infringe on the claims as its commercially available devices could not be programmed to frequencies that would infringe and that devices that could be programmed to high frequency that are being used in clinical trials are included in safe harbor provisions. This leaves the door open in the event that Boston commercially launches a device within the frequency ranges referenced above, Kaczor writes. She believes, however, that even if Boston moves to launch a high frequency device in the United States, the company would likely have to file for FDA approval following the completion of its high-frequency trial. Despite some level of uncertainty this ruling may bring, Nevro's risk/reward is favorable, Kaczor contends. She keeps an Outperform rating on the shares.
07/25/18
LEER
07/25/18
NO CHANGE
Target $90
LEER
Outperform
Nevro selloff overdone, says Leerink
Leerink analyst Danielle Antalffy is defending Nevro (NVRO) shares after a 26% selloff in response to a summary judgment ruling in which either the company's patents were ruled invalid or Boston Scientific (BSX) was ruled to not infringe. The analyst believes that even in a worst-case scenario, namely one in which Nevro's patents are invalidated, allowing other manufacturers to pursue high frequency therapy, the company would still be able to grow sales by about 5% in 2019. Antalffy reiterates an Outperform rating and $90 price target on Nevro's shares as she continues to believe the company's fundamentals remain relatively strong, particularly given where the stock is currently trading.
07/25/18
ADAM
07/25/18
NO CHANGE
Target $80
ADAM
Buy
Nevro weakness a buying opportunity, says Canaccord
Canaccord analyst Jason Mills said the weakness in Nevro (NVRO) following a summary judgment announced yesterday in its patent dispute with Boston Scientific (BSX) is a buying opportunity. The analyst said the move yesterday priced in a worst-case scenario, implying Nevro will lose all IP protection over its HF-10kHz technology, but he believes the current situation is more nuanced and the ultimate outcomes remain fluid. He believes the market overreacted and he recommends investors buy the weakness. Mills reiterated his Buy rating and $80 price target on Nevro shares.
07/25/18
JPMS
07/25/18
NO CHANGE
Target $77
JPMS
Overweight
Nevro selloff yesterday a 'clear buying opportunity,' says JPMorgan
JPMorgan analyst Robbie Marcus views yesterday's selloff in shares of Nevro (NVRO) as a "clear buying opportunity." The headlines suggest Boston Scientific (BSX) was the clear winner in the summary judgment, but the "nuance in the actual ruling swings this in favor of Nevro," Marcus tells investors in a research note. The analyst's interpretation is that while Boston doesn't infringe Nevro's three remaining patents with its current trials and U.S. commercialized tonic stimulation devices, the ruling implies that any attempt to actually commercialize a high-frequency device in the U.S. remains an infringement of Nevro's remaining patents '102 and '472. While Nevro's systems claims patents were ruled invalid, the company's broader method claim patents were upheld, Marcus writes. He keeps an Overweight rating on Nevro with a $77 price target. The stock closed yesterday down 26%, or $15.78, to $44.22.
PEN Penumbra
$134.78

3.275 (2.49%)

06/28/18
BOFA
06/28/18
NO CHANGE
Target $150
BOFA
Buy
Street underestimating Penumbra competition, says BofA/Merrill
BofA/Merrill analyst Bob Hopkins notes that over the last few weeks, he has had the opportunity to conduct extensive diligence on the stroke market and on the competitive technologies coming to challenge Penumbra's market-leading aspiration system. His conversations with stroke-focused physicians from around the world suggest that, in the short-term, the Street may be underestimating the 4-5 new competitors coming to market. While Hopkins does not necessarily think numbers are too high and the long-term outlook remains strong, he believes short-term there is "greater uncertainty." The analyst reiterates a Buy rating and $150 price target on the shares.
05/31/18
WELS
05/31/18
NO CHANGE
Target $180
WELS
Outperform
Penumbra price target raised to $180 from $150 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Penumbra to $180 from $150 following "very strong" Q1 results and meeting with the company's management. The analyst believes management is confident in the outlook of the stroke market and expects Penumbra to remain in a leading position given its advanced technology. He reiterates an Outperform rating on the shares.
05/09/18
BMOC
05/09/18
NO CHANGE
Target $140
BMOC
Market Perform
Penumbra price target raised to $140 from $115 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Penumbra to $140 after the company's Q1 results, saying its constant currency revenue growth has accelerated to 36% from mid-20s seen for most of 2017. The analyst notes that it is not yet clear whether the "ischemic stroke market has entered a new, hyperbolic phase of growth or if it reflects uneven dynamics", but will look to verify the trend. Wuensch keeps her Market Perform rating to reflect the current risk-reward on the company.
08/10/18
WELS
08/10/18
NO CHANGE
Target $180
WELS
Outperform
Penumbra checks confirm 'strong' growth continuing, says Wells Fargo
Wells Fargo analyst Larry Biegelsen says his recent channel checks confirm that Penumbra's "strong" growth momentum in the stroke market is continuing. Further, there should be a shift towards more aspiration-first procedures driven by the recent release of Compass data, Biegelsen tells investors in a research note titled "JET-ENGINE Ready For Take-Off!" The analyst believes Penumbra will "continue to lead the field with its innovative technology" with the new Engine pump that launched recently and the Jet catheter that is pending FDA approval. He keeps an Outperform rating on the shares with a $180 price target.
VCYT Veracyte
$12.25

-0.04 (-0.33%)

11/07/17
JANY
11/07/17
DOWNGRADE
JANY
Neutral
Veracyte downgraded to Neutral from Buy at Janney Capital
11/07/17
PIPR
11/07/17
DOWNGRADE
Target $8
PIPR
Neutral
Veracyte downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Veracyte to Neutral after the company missed Q3 revenue expectations and guided Q4 and 2018 well below estimates. The company, now more than ever, is a "show-me story," Quirk tells investors in a post-earnings research note. He cut his price target for the shares to $8 from $10.
07/24/18
PIPR
07/24/18
NO CHANGE
Target $11
PIPR
Neutral
Veracyte price target raised to $11 from $7 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Veracyte to $11 following the company's Q2 sales beat and increased 2018 guidance. Veracyte is entering a "new multi-faceted growth cycle" and deserves a premium multiple, Quirk tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares but has a "positive bias." He views the new guidance as "not only achievable but potentially beatable."
11/07/17
11/07/17
DOWNGRADE
Target $9

Neutral
Veracyte downgraded to Neutral on slow Percepta traction at Janney Capital
As previously reported, Janney Capital analyst Paul Knight downgraded Veracyte to Neutral from Buy citing slower than expected traction for its new lung cancer diagnostic, Percepta, paired with lower than expected growth for its core thyroid test. Knight, who lowered his FY18 revenue estimate for Veracyte to $83M from about $100M, cut his fair value estimate on the stock to $9 from $15.

TODAY'S FREE FLY STORIES

GMRE

Global Medical REIT

$9.53

-0.12 (-1.24%)

07:58
12/12/18
12/12
07:58
12/12/18
07:58
Syndicate
Global Medical REIT 3.5M share Spot Secondary priced at $9.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ATH

Athene Holding

, LNC

Lincoln National

$54.48

-0.98 (-1.77%)

07:56
12/12/18
12/12
07:56
12/12/18
07:56
Recommendations
Athene Holding, Lincoln National analyst commentary  »

Athene Holding price…

ATH

Athene Holding

LNC

Lincoln National

$54.48

-0.98 (-1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

IAC

IAC

$179.00

-0.28 (-0.16%)

07:56
12/12/18
12/12
07:56
12/12/18
07:56
Recommendations
IAC analyst commentary  »

Jefferies keeps IAC as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMN

AMN Healthcare

$59.28

0.4 (0.68%)

07:56
12/12/18
12/12
07:56
12/12/18
07:56
Conference/Events
AMN Healthcare management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ARMK

Aramark

$31.18

-4.3 (-12.12%)

07:55
12/12/18
12/12
07:55
12/12/18
07:55
Recommendations
Aramark analyst commentary  »

Aramark price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$30.31

-0.75 (-2.41%)

07:55
12/12/18
12/12
07:55
12/12/18
07:55
Conference/Events
Unum Group to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BIIB

Biogen

$319.85

0.22 (0.07%)

07:55
12/12/18
12/12
07:55
12/12/18
07:55
Conference/Events
Biogen to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AWK

American Water

$96.49

-1.01 (-1.04%)

07:54
12/12/18
12/12
07:54
12/12/18
07:54
Recommendations
American Water analyst commentary  »

American Water price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$4.59

-0.07 (-1.50%)

07:51
12/12/18
12/12
07:51
12/12/18
07:51
Recommendations
Ashford Hospitality analyst commentary  »

Ashford Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$51.08

-1.44 (-2.74%)

07:50
12/12/18
12/12
07:50
12/12/18
07:50
Recommendations
Dave & Buster's analyst commentary  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

07:50
12/12/18
12/12
07:50
12/12/18
07:50
General news
Treasury Market Outlook: Treasury yields are fractionally higher »

Treasury Market Outlook:…

CASY

Casey's General Stores

$129.50

9.86 (8.24%)

07:49
12/12/18
12/12
07:49
12/12/18
07:49
Recommendations
Casey's General Stores analyst commentary  »

Casey's General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOB

Live Oak Bancshares

$13.67

-2.98 (-17.90%)

07:49
12/12/18
12/12
07:49
12/12/18
07:49
Downgrade
Live Oak Bancshares rating change  »

Live Oak Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$161.43

-0.08 (-0.05%)

07:48
12/12/18
12/12
07:48
12/12/18
07:48
Conference/Events
ASML management to meet with KeyBanc »

Meeting to be held on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LOB

Live Oak Bancshares

$13.67

-2.98 (-17.90%)

07:47
12/12/18
12/12
07:47
12/12/18
07:47
Upgrade
Live Oak Bancshares rating change  »

Live Oak Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$189.58

-3.36 (-1.74%)

07:47
12/12/18
12/12
07:47
12/12/18
07:47
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

VST

Vistra Energy

$23.92

0.28 (1.18%)

07:45
12/12/18
12/12
07:45
12/12/18
07:45
Recommendations
Vistra Energy analyst commentary  »

Vistra Energy shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABIL

Ability

$2.37

0.005 (0.21%)

07:45
12/12/18
12/12
07:45
12/12/18
07:45
Hot Stocks
Ability regains Nasdaq compliance »

Ability announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$15.45

0.02 (0.13%)

07:44
12/12/18
12/12
07:44
12/12/18
07:44
Recommendations
Array BioPharma analyst commentary  »

Array BioPharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.02

0.02 (0.11%)

07:44
12/12/18
12/12
07:44
12/12/18
07:44
Initiation
iQIYI initiated  »

iQIYI initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THS

TreeHouse

$51.64

2.69 (5.50%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Recommendations
TreeHouse analyst commentary  »

TreeHouse price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$2.78

0.07 (2.58%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Hot Stocks
KemPharm presents research on IV abuse potential of SDX at ACNP »

KemPharm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$32.17

-0.08 (-0.25%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Downgrade
Southern Copper rating change  »

Southern Copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THS

TreeHouse

$51.64

2.69 (5.50%)

07:43
12/12/18
12/12
07:43
12/12/18
07:43
Recommendations
TreeHouse analyst commentary  »

TreeHouse price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASR

Asur

$141.69

-0.66 (-0.46%)

07:42
12/12/18
12/12
07:42
12/12/18
07:42
Upgrade
Asur rating change  »

Asur upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.